Metraipolis › archive › dc_fdc5386e4c76

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease — Europe PMC PMID:42499715

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42499715
DOI
10.1002/jpr3.70212
License (as archived)
solo-consultazione
Archived
2026-10-18T11:18:20.359Z
SHA-256 of the archived text
5233248d4d5a9529a18b26f8114ec5deee2135213200393271cb5e4f7bc9e6c1
Stable URL of this page
https://metraipolis.com/documento/dc_fdc5386e4c76

How to cite

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease — Europe PMC PMID:42499715 — Europe PMC (en), https://europepmc.org/article/MED/42499715 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fdc5386e4c76 (Metraipolis archive dc_fdc5386e4c76, sha256 5233248d4d5a9529a18b26f8114ec5deee2135213200393271cb5e4f7bc9e6c1)
BibTeX
@misc{dcfdc5386e4c76,
  title = {Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease — Europe PMC PMID:42499715},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42499715},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fdc5386e4c76; sha256 5233248d4d5a9529a18b26f8114ec5deee2135213200393271cb5e4f7bc9e6c1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42499715. Agents can read the archived copy with the MCP tool read_document.